Potentiation of fibrinolytic therapy in acute myocardial infarction: Expanding the role of ACE-inhibitors

Thrombosis and Haemostasis

Volumn 88, Issue 2, 2002, Pages 176-178

  Andreotti, Felicita ^a   Biondi Zoccai, Giuseppe G L ^a  

^a NONE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAPTOPRIL; CREATINE KINASE; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FIBRINOLYTIC AGENT; HEPARIN; PLACEBO; PLASMIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; RAMIPRIL; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE;

ACUTE HEART INFARCTION; ARTERY THROMBOSIS; CARDIOVASCULAR RISK; CLINICAL TRIAL; DEVELOPED COUNTRY; DRUG CONTRAINDICATION; DRUG EFFECT; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; EVIDENCE BASED MEDICINE; FIBRINOLYTIC THERAPY; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE REVASCULARIZATION; HEART VENTRICLE REMODELING; HIGH RISK PATIENT; HUMAN; INTENSIVE CARE; NONHUMAN; NOTE; PARTIAL THROMBOPLASTIN TIME; PATIENT MONITORING; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REPERFUSION; SURVIVAL; TREATMENT PLANNING;

EID: 0036332102     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1613183     Document Type: Note

References (25)

1. Acute myocardial infarction
2. The illusion of reperfusion: Does anyone achieve optimal reperfusion during acute myocardial infarction?
3. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2
4. Plasminogen-activator inhibitor type 1 and coronary artery disease
5. Plasminogen activator inhibitor 1: Molecular aspects and clinical importance
6. Inhibition of plasminogen activator inhibitor-1 activity results in promotion of endogenous thrombolysis and inhibition of thrombus extension in models of experimental thrombosis
7. Plasminogen activator inhibitor-1 is a major determinant of arterial thrombolysis resistance
8. Correlation of baseline plasminogen activator inhibitor activity with patency of the infarct artery after thrombolytic therapy in acute myocardial infarction
9. Correlation between baseline plasminogen activator inhibitor levels and clinical outcome during therapy with tissue plasminogen activator for acute myocardial infarction
10. Pretreatment plasminogen activator inhibitor-1 (PAI-1) levels and the outcome of thrombolysis with streptokinase in patients with acute myocardial infarction
11. Major circadian fluctuations in fibrinolytic factors and possible relevance to time of onset of myocardial infarction, sudden death and stroke
12. Genetic variation at the plasminogen activator inhibitor-1 locus is associated with altered levels of plasma plasminogen activator inhibitor-1 activity
13. The 4G/5G polymorphism of PAI-1 promoter gene and the risk of myocardial infarction: A meta-analysis
14. Defective fibrinolytic states as triggers of myocardial infarction: The cardiologist's view
15. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure
16. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: Results of the Survival and Ventricular Enlargement trial
17. Effect of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients
18. Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. A potential link between the renin-angiotensin system and thrombosis
19. Angiotensin II increases plasminogen activator inhibitor type 1 and tissue-type plasminogen activator messenger RNA in cultured rat aortic smooth muscle cells
20. Angiotensin, fibrinolysis, and vascular homeostasis
21. Effect of activation and inhibition of the renin-angiotensin system on plasma PAI-1
22. Effects of captopril therapy on endogenous fibrinolysis in men with recent, uncomplicated myocardial infarction
23. Effects of ramipril on plasma fibrinolytic balance in patients with acute anterior myocardial infarction. HEART Study Investigators
24. Effects of acute angiotensin II type 1 receptor antagonism and angiotensin converting enzyme inhibition on plasma fibrinolytic parameters in patients with heart failure
25. Ramipril prior to thrombolysis attenuates the early increase of PAI-1 in patients with acute myocardial infarction